Progetto di ricerca

H2020 ALTERNATIVE (DSB.AD008.721)

Area tematica

Scienze biomediche

Area progettuale

Tecnologie Applicate alle Scienze Biomediche (DSB.AD008)

Struttura responsabile del progetto di ricerca

Istituto di fisiologia clinica (IFC)

Responsabile di progetto

FEDERICO VOZZI
Telefono: 0503152216
E-mail: vozzi@ifc.cnr.it

Abstract

ALTERNATIVE will develop an innovative platform able to detect the cardiotoxicity of chemicals and their bio-transformation products. The novel platform will enable regulators and industry to identify, quantify and prevent cardiotoxic co-exposures to industrial chemicals and pharmaceuticals in a cost-effective way. ALTERNATIVE will particularly focus on cardiotoxic effects on older people, which is of high relevance in view of the ageing EU population and the high spread of cardiovascular diseases. The platform will consist of a three-dimensional tissue engineering in-vitro model mimicking the human cardiac tissue, coupled with a reliable, high-throughput monitoring system based on multi-omics analyses, and integrated into a Machine Learning (ML) risk assessment tool. In addition, ALTERNATIVE will modify the tissue model to reproduce the aged myocardial tissue and elucidate the adverse effects of chemicals on older people. ALTERNATIVE?s proof-of-concept validation will be performed on well-known mixtures of pollutants, affecting different environmental compartments, and selected via epidemiological, toxicological and modelling expertise. ALTERNATIVE will also provide systematic rev

Obiettivi

ALTERNATIVE will develop an innovative platform able to detect the cardiotoxicity of chemicals and their bio-transformation products. The novel platform will enable regulators and industry to identify, quantify and prevent cardiotoxic co-exposures to industrial chemicals and pharmaceuticals in a cost-effective way. ALTERNATIVE will particularly focus on cardiotoxic effects on older people, which is of high relevance in view of the ageing EU population and the high spread of cardiovascular diseases. The platform will consist of a three-dimensional tissue engineering in-vitro model mimicking the human cardiac tissue, coupled with a reliable, high-throughput monitoring system based on multi-omics analyses, and integrated into a Machine Learning (ML) risk assessment tool. In addition, ALTERNATIVE will modify the tissue model to reproduce the aged myocardial tissue and elucidate the adverse effects of chemicals on older people. ALTERNATIVE?s proof-of-concept validation will be performed on well-known mixtures of pollutants, affecting different environmental compartments, and selected via epidemiological, toxicological and modelling expertise. ALTERNATIVE will also provide systematic rev

Data inizio attività

01/10/2021

Parole chiave

Environmental toxicology, Safety Pharmacology,, Toxicology,

Ultimo aggiornamento: 28/01/2025